Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=45

The Utility of Telemedicine in the Management of Migraine

Migraine Headaches

Bottom Line

View on ClinicalTrials.gov: NCT01706003 ↗
Enrolled (actual)
45
Serious AEs
6.7%
Results posted
Oct 2019
Primary outcome: Primary: Assess the Utility of Telemedicine for Follow-up Care in a Headache Medicine Practice — 87; 92.7 percentage of scheduled appointments

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
—
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Texas Southwestern Medical Center
Primary completion
Oct 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Assess the Utility of Telemedicine for Follow-up Care in a Headache Medicine Practice		 87; 92.7 —

Summary

Patients will be randomly assigned to receive their follow-up care via telemedicine or in-office visits.

Eligibility Criteria

Inclusion Criteria:• Ages 18 - 89 years

  • Diagnosis of migraine with or without aura, menstrual migraine, hemiplegic migraine
  • Able to provide informed consent
  • Able, in the opinion of the investigator, to reliably perform all aspects of the study
  • Ownership of or access to a computer and high speed internet

Criteria for Exclusion of Subjects:

  • Age less than 18 years
  • Headache type is not migraine
  • No ownership or access to a computer or high speed internet
  • Unfamiliar with basic computer operations or uncomfortable using a computer
  • Unwilling to participate
  • Unable to read English (because of assessment tools)
  • History of another medical, psychiatric, social or behavioral problem that, in the opinion of the investigator, makes it unlikely that they will be able to complete the study activities. Questions regarding mood and anxiety are asked of all patients as part of their initial evaluation for headache.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01706003). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search